992 related articles for article (PubMed ID: 16861943)
41. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
Tran HTB; Acharya MK; McKay DB; Sayegh MH; Carpenter CB; Auchincloss H; Kirkman RL; Milford EL
J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
[TBL] [Abstract][Full Text] [Related]
42. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
43. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
[TBL] [Abstract][Full Text] [Related]
44. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
van den Akker JM; Hené RJ; Hoitsma AJ
Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
[TBL] [Abstract][Full Text] [Related]
45. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
[No Abstract] [Full Text] [Related]
46. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
47. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
48. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
Boswell A; Evans L; Rigg K; Shehata M
Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
[TBL] [Abstract][Full Text] [Related]
49. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
[TBL] [Abstract][Full Text] [Related]
50. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
[TBL] [Abstract][Full Text] [Related]
51. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
52. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression.
Rasaiah SB; Light JA; Sasaki TM; Currier CB
Clin Transplant; 2000 Aug; 14(4 Pt 2):409-12. PubMed ID: 10946780
[TBL] [Abstract][Full Text] [Related]
53. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
54. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
55. Daclizumab to prevent rejection after cardiac transplantation.
Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
[TBL] [Abstract][Full Text] [Related]
56. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
Cole E; Landsberg D; Russell D; Zaltzman J; Kiberd B; Caravaggio C; Vasquez AR; Halloran P
Transplantation; 2001 Sep; 72(5):845-50. PubMed ID: 11571448
[TBL] [Abstract][Full Text] [Related]
57. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
[TBL] [Abstract][Full Text] [Related]
58. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
60. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study.
Gheith OA; Nematalla AH; Bakr MA; Refaie A; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2011 Apr; 9(2):121-7. PubMed ID: 21453230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]